Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

T-Cell Depleted (TCD) Hematopoietic Stem Cell (HSC) Boosts From the Original Donor without Conditioning for Poor Graft Function (PGF) Following Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

Michael A. Rosenzweig, MD, Nancy A. Kernan, MD, Trudy N Small, MD, Molly Maloy, Ann A. Jakubowski, MD, PhD, Esperanza B Papadopoulos, MD, Miguel-Angel Perales, MD, Farid Boulad, MD, Sergio Giralt, MD, James W Young, MD, Richard J. O'Reilly, MD, Hugo R Castro-Malaspina, MD

Blood (2011) 118 (21): 1942.

https://doi.org/10.1182/blood.V118.21.1942.1942

Published: 2011

Journal Articles

T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation with Busulfan, Melphalan, and Fludarabine Conditioning Followed by Post Transplantation Donor Lymphocyte Infusions for Patients with Relapsed Multiple Myeloma and High-Risk Cytogenetics

Guenther Koehne, MD PhD, Heather Landau, MD, Hani Hassoun, MD, Alex Lesokhin, MD, Nikoletta Lendvai, MD PhD, Michael A. Rosenzweig, MD, Glenn Heller, PhD, Sergio Giralt, MD

Blood (2011) 118 (21): 1992.

https://doi.org/10.1182/blood.V118.21.1992.1992

Published: 2011

Journal Articles

Cancer-Testis (CT) Antigen Expression In AL Amyloidosis

Michael A. Rosenzweig, MD, Heather Landau, MD, Achim A Jungbluth, MD, Nicole Hanson, BSc, Denise Frosina, BSc, Maria Arcila, MD, Raymond L. Comenzo, MD, Guenther Koehne, MD, PhD

Blood (2010) 116 (21): 4055.

https://doi.org/10.1182/blood.V116.21.4055.4055

Published: 2010

Journal Articles

Outcomes Following Salvage Autologous Stem Cell Transplant for Multiple Myeloma

Daniel E Fein, Hani Hassoun, MD, Raymond L. Comenzo, MD, Alex Lesokhin, Nikoletta Lendvai, MD, PhD, David Chung, MD, PhD, Adam Cohen, Michael A. Rosenzweig, MD, Danielle Chimento, Xiaoyu Jia, Stephen Nimer, Sergio Giralt, MD, Heather Landau, MD

Blood (2010) 116 (21): 1353.

https://doi.org/10.1182/blood.V116.21.1353.1353

Published: 2010

Journal Articles

Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy

Heather Landau, MD, Hani Hassoun, MD, Michael A. Rosenzweig, MD, Christina Bello, Elizabeth Hoover, Elyn Riedel, Alex Lesokhin, MD, Nikoletta Lendvai, MD, PhD, Adam Cohen, MD, Stephen Nimer, Raymond L. Comenzo, MD

Blood (2010) 116 (21): 2391.

https://doi.org/10.1182/blood.V116.21.2391.2391

Published: 2010

NARROW

T-Cell Depleted (TCD) Hematopoietic Stem Cell (HSC) Boosts From the Original Donor without Conditioning for Poor Graft Function (PGF) Following Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation with Busulfan, Melphalan, and Fludarabine Conditioning Followed by Post Transplantation Donor Lymphocyte Infusions for Patients with Relapsed Multiple Myeloma and High-Risk Cytogenetics

Cancer-Testis (CT) Antigen Expression In AL Amyloidosis

Outcomes Following Salvage Autologous Stem Cell Transplant for Multiple Myeloma

Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy

Email alerts

ASH Publications

American Society of Hematology

T-Cell Depleted (TCD) Hematopoietic Stem Cell (HSC) Boosts From the Original Donor without Conditioning for Poor Graft Function (PGF) Following Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation with Busulfan, Melphalan, and Fludarabine Conditioning Followed by Post Transplantation Donor Lymphocyte Infusions for Patients with Relapsed Multiple Myeloma and High-Risk Cytogenetics

Cancer-Testis (CT) Antigen Expression In AL Amyloidosis

Outcomes Following Salvage Autologous Stem Cell Transplant for Multiple Myeloma

Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only